Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129864 | 0.83 | CYP3A4 (0.66) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL270275 | 0.82 | MAPT (0.58) | CYP3A4CYP2D6ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL812679 | 0.80 | ALDH1A1 (0.83) | CYP3A4ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL12042479 | 0.79 | ALDH1A1 (0.76) | CYP3A4ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL8487067 | 0.77 | MAPT (0.56) | CYP3A4CYP2D6ALDH1A1HTTPOLB | |
| SCHEMBL24254524 | 0.77 | CYP3A4 (0.61) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL4880963 | 0.76 | CYP3A4 (0.64) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL1040954 | 0.74 | ALDH1A1 (0.73) | CYP3A4ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL13433558 | 0.74 | ALDH1A1 (0.73) | CYP3A4ALDH1A1HTTPOLBSMN1; SMN2 | |
| SCHEMBL7364379 | 0.74 | ALDH1A1 (0.68) | CYP3A4ALDH1A1HTTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-11865176-B2 | Compositions and methods of modulating anti-tumor immunity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| WO-2023227518-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282435-A1 | FORMULATIONS OF ACTIVE PHARMACEUTICAL INGREDIENTS AND EXCIPIENTS IN ICELLS VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282448-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2007089069-A1 | PHENYL IMIDAZOL SULFONAMIDE DERIVATIVES, THE PREPARATION METHOD THEREOF AND THE WHITENING COSMETIC COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | CYP3A4 4839/4885CYP2D6 4871/4885PSEN1 1852/4885 |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | LIPA, LIPE, CEL | CYP3A4 1097/4885CYP2D6 557/4885PSEN1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.